Kurt Francis
Pulmonary Disease · Salt Lake City, UTNPI 1578588018
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,950 of the $4,722 with a category attached, or 83.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations.
Across 292 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$1K
- AstraZeneca$757
- GSK$657
- Boehringer Ingelheim$344
- Sunovion Pharmaceuticals Inc.$301
- Sanofi$193
- plus $1K from 23 others
What the payments were for
- Consulting fees$501%
- Speaking & faculty fees$72215%
- Food & beverage$3,95084%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 18 | $1,077 |
| AstraZeneca | 38 | $757 |
| GSK | 75 | $657 |
| Boehringer Ingelheim | 26 | $344 |
| Sunovion Pharmaceuticals Inc. | 27 | $301 |
| Sanofi | 12 | $193 |
| Actelion Pharmaceuticals US, Inc. | 10 | $162 |
| Amgen | 7 | $128 |
| Johnson & Johnson | 7 | $109 |
| Amarin Pharma, Inc. | 6 | $89 |
| Boston Scientific | 6 | $84 |
| Pfizer | 6 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Novartis | 6 | $78 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| Electromed, Inc. | 11 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Circassia Inc. | 3 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $51 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Portola Pharmaceuticals, LLC | 4 | $48 |
| Chiesi USA, Inc. | 3 | $42 |
| Advanced Respiratory, Inc | 2 | $25 |
| Abbott | 1 | $14 |
| Gilead | 1 | $13 |
| Harmony Biosciences LLC | 1 | $12 |
| Pulmonx Corporation | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,722 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.